21:53 , Apr 13, 2018 |  BioCentury  |  Product Development

Self-driving CARs

Novartis AG, Gilead Sciences Inc. and now Pfizer Inc. have taken different approaches to managing their CAR T cell assets, but the three companies appear to be converging on the notion that developing the technology...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
22:08 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

CART-BCMA: Preliminary Ph I data

Preliminary data from 6 evaluable patients with relapsed or refractory MM in an open-label, U.S. Phase I trial showed that IV CART-BCMA over 3 days led to 1 stringent complete response, 1 very good partial...
00:22 , Dec 7, 2016 |  BC Extra  |  Clinical News

BCMA-targeting therapies in ASH spotlight

At the American Society of Hematology meeting in San Diego, presentations late Monday highlighted data from Phase I studies of two candidates targeting tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17 ; CD269)...